Charles River Laboratories International (CRL) Accumulated Expenses (2009 - 2025)

Charles River Laboratories International (CRL) has reported Accumulated Expenses for 17 consecutive years, with $270.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Expenses rose 50.53% year-over-year to $270.1 million; the TTM figure through Dec 2025 stood at $270.1 million (up 50.53% YoY), while the FY2025 annual figure was $270.1 million, up 50.53% from the prior year.
• Accumulated Expenses came in at $270.1 million for Q4 2025 at Charles River Laboratories International, roughly flat from $269.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $270.1 million in Q4 2025, with the low at $176.1 million in Q2 2023.
• Average Accumulated Expenses over 5 years is $214.8 million, with a median of $210.7 million recorded in 2023.
• Across the five-year window, Accumulated Expenses soared 58.74% in 2021 and declined 22.51% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $228.8 million in 2021, then dropped by 13.86% to $197.1 million in 2022, then advanced by 8.23% to $213.3 million in 2023, then retreated by 15.88% to $179.4 million in 2024, then surged by 50.53% to $270.1 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $270.1 million, $269.7 million, and $227.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.